Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Day

Showing results (81-90 of 95) with videos related to

Pageof 10
Sort By:
Clinical Pharmacokinetics|April 22, 2024
Development of a Weight-Band Dosing Approach for Vosoritide in Children with Achondroplasia Using a Population Pharmacokinetic ModelYulan Qi, Ming Liang Chan, Diane R Mould, et al.
Plos One|September 9, 2017
Application of a whole blood mycobacterial growth inhibition assay to study immunity against Mycobacterium tuberculosis in a high tuberculosis burden populationRichard Baguma, Adam Penn-Nicholson, Erica Smit, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 21, 2024
Persistent growth-promoting effects of vosoritide in children with achondroplasia are accompanied by improvements in physical and social aspects of health-related quality of lifeRavi Savarirayan, Melita Irving, William R Wilcox, et al.
Nature Neuroscience|July 21, 2015
The role of ventral striatal cAMP signaling in stress-induced behaviorsFlorian Plattner, Kanehiro Hayashi, Adan Hernández, et al.
Clinical Pharmacokinetics|August 25, 2021
Pharmacokinetics and Exposure-Response of Vosoritide in Children with AchondroplasiaMing Liang Chan, Yulan Qi, Kevin Larimore, et al.
Frontiers in Immunology|March 15, 2021
Inflammatory Determinants of Differential Tuberculosis Risk in Pre-Adolescent Children and Young AdultsRichard Baguma, Stanley Kimbung Mbandi, Miguel J Rodo, et al.
Vaccine|July 6, 2025
Humoral, T cell and immune gene expression responses to SARS-CoV-2 vaccination in a small group of children with previous MIS-CTimothy F Spracklen, Jonathan Day, Hamza Van Der Ross, et al.
The New England Journal of Medicine|July 4, 2019
C-Type Natriuretic Peptide Analogue Therapy in Children with AchondroplasiaRavi Savarirayan, Melita Irving, Carlos A Bacino, et al.
Hemasphere|June 8, 2026
Access to diagnosis using liquid biopsy (ADLiB): Identifying lymphoma in a tuberculosis-endemic settingKatherine Antel, Nina Xiong, Mwanasha Merrill, et al.
The Lancet. Child & Adolescent Health|November 20, 2023
Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trialRavi Savarirayan, William R Wilcox, Paul Harmatz, et al.
Pageof 10

Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
Clinical Pharmacokinetics|April 22, 2024
Development of a Weight-Band Dosing Approach for Vosoritide in Children with Achondroplasia Using a Population Pharmacokinetic ModelYulan Qi, Ming Liang Chan, Diane R Mould, et al.
Plos One|September 9, 2017
Application of a whole blood mycobacterial growth inhibition assay to study immunity against Mycobacterium tuberculosis in a high tuberculosis burden populationRichard Baguma, Adam Penn-Nicholson, Erica Smit, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 21, 2024
Persistent growth-promoting effects of vosoritide in children with achondroplasia are accompanied by improvements in physical and social aspects of health-related quality of lifeRavi Savarirayan, Melita Irving, William R Wilcox, et al.
Nature Neuroscience|July 21, 2015
The role of ventral striatal cAMP signaling in stress-induced behaviorsFlorian Plattner, Kanehiro Hayashi, Adan Hernández, et al.
Clinical Pharmacokinetics|August 25, 2021
Pharmacokinetics and Exposure-Response of Vosoritide in Children with AchondroplasiaMing Liang Chan, Yulan Qi, Kevin Larimore, et al.
Frontiers in Immunology|March 15, 2021
Inflammatory Determinants of Differential Tuberculosis Risk in Pre-Adolescent Children and Young AdultsRichard Baguma, Stanley Kimbung Mbandi, Miguel J Rodo, et al.
Vaccine|July 6, 2025
Humoral, T cell and immune gene expression responses to SARS-CoV-2 vaccination in a small group of children with previous MIS-CTimothy F Spracklen, Jonathan Day, Hamza Van Der Ross, et al.
The New England Journal of Medicine|July 4, 2019
C-Type Natriuretic Peptide Analogue Therapy in Children with AchondroplasiaRavi Savarirayan, Melita Irving, Carlos A Bacino, et al.
Hemasphere|June 8, 2026
Access to diagnosis using liquid biopsy (ADLiB): Identifying lymphoma in a tuberculosis-endemic settingKatherine Antel, Nina Xiong, Mwanasha Merrill, et al.
The Lancet. Child & Adolescent Health|November 20, 2023
Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trialRavi Savarirayan, William R Wilcox, Paul Harmatz, et al.
Pageof 10